drugset / Trial / NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.
Timeline
- Start
- 2019-10-09
- Primary completion
- 2024-11-30
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EMZADIRIB | Small molecule | — | Oral |
| Background | Bendamustine | Small molecule | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |